Micro Aftermath Archived

Biogen's acquisition of Apellis Pharmaceuticals

Activity declining — narrative losing relevance.

Score 0.3

Velocity ▲ 0.0

Articles 7

Sources 2

Top Movers

Ticker	Sector	Change
BIIB	Healthcare	+21.7%
APLS	Healthcare	+1.6%

Sentiment Timeline

Sector Performance

Stock Performance

Event Timeline

Apr 30, 2026 Why Biogen Stock Was a Winner on Wednesday Bullish

Apr 16, 2026 This Healthcare Stock Has Made Long-Term Investors Rich -- Can It Keep … Bearish

Apr 07, 2026 Why Biogen Stock Got Mashed on Monday Bearish

Apr 02, 2026 Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio Bullish

Apr 01, 2026 Why Biogen Stock Sank While the Market Soared on Thursday Neutral

Why Biogen Stock Was a Winner on Wednesday Nasdaq · Apr 30, 2026 Mixed Why Biogen Stock Got Mashed on Monday Nasdaq · Apr 07, 2026 Mixed Apellis Pharma Skyrockets on Biogen Deal. Is It Too Late to Chase APLS Stock? Yahoo Finance · Apr 02, 2026 Mixed Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio Yahoo Finance · Apr 02, 2026 Mixed

Top Movers

Ticker	Sector	Change
BIIB	Healthcare	+21.7%
APLS	Healthcare	+1.6%

🤖 AI Overview

Biogen Inc. (NASDAQ:BIIB) announced on Tuesday, May 17, its acquisition of Apellis Pharmaceuticals Inc. (NASDAQ:APLS) for approximately $5.6 billion in cash, valuing APLS shares at $41 each, a 140% premium. This deal, expected to close in Q3 2022, adds C3 therapies to Biogen's portfolio, marking a strategic pivot away from its traditional strength in multiple sclerosis treatments.

The acquisition drove a significant market impact. Biogen stock rose 1.5% on Wednesday, while APLS shares surged to a two-year high, benefiting from the 140% upside. However, Biogen's stock also experienced volatility, dropping 2.5% on Monday due to anticipated higher spending on milestone payments and R&D activities. Biogen's quarterly updates have not been impressive, casting uncertainty over its long-term prospects.

Next, investors should watch for the closing of the acquisition in Q3 2022. Additionally, they should monitor Biogen's quarterly updates and earnings releases to assess the company's ability to drive top-line growth beyond regulatory progress. Lastly, the market will closely follow the integration of Apellis' C3 therapies into Biogen's portfolio and their potential impact on the company's future performance.

AI Overview as of Apr 30, 2026

Timeline

First SeenApr 01, 2026

Last UpdatedApr 01, 2026

Biogen's acquisition of Apellis Pharmaceuticals

Top Movers

Sentiment Timeline

Sector Performance

Stock Performance

Event Timeline

Related Articles